Kate Enters Collaboration with Capsida to Manufacture its Next-Generation Gene Therapies

Rare Daily Staff

Strategic partnership leverages Capsida’s next-generation manufacturing capabilities to enable development of KateTx’s gene therapy medicines for muscle and heart diseases.

Kate Therapeutics and Capsida Biotherapeutics entered into a strategic partnership to leverage Capsida’s expertise and adeno-associated virus manufacturing capabilities to enable KateTx’s initial internal portfolio of muscle and heart disease programs.

Under the terms of the agreement, Capsida will provide GMP manufacturing of KateTx’s gene thera delivered to specific organ systems while simultaneously limiting exposure to non-targeted organs.

“Capsida possesses end-to-end expertise–which includes AAV capsid engineering, preclinical, clinical, and state-of-the-art manufacturing,” said Peter Anastasiou, CEO of Capsida Biotherapeutics. “We will be able to leverage our established capabilities in AAV manufacturing and support a peer company to reach patients in a complementary space, while continuing to advance our own internal and partnered pipeline in CNS and ophthalmology.”

KateTx’s publicly disclosed internal programs include myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy, which are two of the leading causes of adult-onset muscular dystrophy.

“KateTx is leading the way in developing capsid and cargo combinations to address muscle and heart diseases in ways that have not been previously possible,” said Kevin Forrest, president and CEO of Kate Therapeutics. “Capsida’s AAV manufacturing capabilities allow us to build our pipeline, de-risk our programs, and advance them into the clinic in the most rapid manner possible, so we can bring much-needed therapies to patients quickly.”

Photo: Peter Anastasiou, CEO of Capsida Biotherapeutics